Concepedia

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Steven D. Gore, Pierre Fenaux, Valeria Santini, John M. Bennett, L.R. Silverman, John F. Seymour, Eva Hellström‐Lindberg, Arlene S. Swern, C.L. Beach, Alan F. List

Haematologica · 2013 · 133 citations · 16 references

DOIFull text

Open access

Abstract

EVALUATION OF PROGNOSTIC MARKERS FOR SURVIVAL IN MDS PATIENTS TREATED WITH AZACITIDINE

References

16

A new look at the statistical model identification

Hirotugu Akaike · IEEE Transactions on Automatic Control · 1974 · 49.6K citations · Full text

, , +16

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.4K citations · Full text

ANew Look at the Statistical Model Identification

HlROTUGU AKAlKE · 2011 · 4.2K citations

, , +17

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

, , +6

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2002 · 1.8K citations